Chenodeoxycholic acid, an endogenous FXR ligand alters adipokines and reverses insulin resistance

Molecular and Cellular Endocrinology

Volumn 414, Issue , 2015, Pages 19-28

  Shihabudeen, Mohamed Sham ^a   Roy, Debasish ^a   James, Joel ^a   Thirumurugan, Kavitha ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Adipokines; Chenodeoxycholic acid; High fat diet; Insulin resistance; Palmitate

Indexed keywords

ADIPONECTIN; CHEMERIN; CHENODEOXYCHOLIC ACID; FARNESOID X RECEPTOR; INSULIN; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR; RESISTIN; RETINOL BINDING PROTEIN 4; TUMOR NECROSIS FACTOR ALPHA; VASPIN; ADIPOCYTOKINE; AUTACOID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; PALMITIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOMODULATION; IMMUNOREGULATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MALE; MORPHOMETRICS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; 3T3 CELL LINE; ADIPOSE TISSUE; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; MOUSE; PATHOLOGY; WISTAR RAT;

3T3-L1 CELLS; ADIPOKINES; ADIPOSE TISSUE; ANIMALS; CHENODEOXYCHOLIC ACID; GENE EXPRESSION REGULATION; INFLAMMATION; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MALE; MICE; PALMITIC ACID; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84937675326     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.07.012     Document Type: Article

References (55)

1. Aguirre V., Uchida T., Yenush L., Davis R., White M.F. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J.Biol. Chem. 2000, 275:9047-9054.
2. Ajuwon K.M., Spurlock M.E. Palmitate activates the NF-κB transcription factor and induces IL-6 and TNFα expression in 3T3-L1 adipocytes. J.Nutr. 2005, 135:1841-1846.
3. Barone M., Francavilla A., Polimeno L., Ierardi E., Romanelli D., Berloco P., Di Leo A., Panella C. Modulation of rat hepatocyte proliferation by bile salts: invitro and invivo studies. Hepatology 1996, 23:1159-1166.
4. Bradley R.L., Fisher F.M., Maratos-Flier E. Dietary fatty acids differentially regulate production of TNF-α and IL-10 by murine 3T3-L1 adipocytes. Obesity 2008, 16:938-944.
5. Cariou B., van Harmelen K., Duran-Sandoval D., van Dijk T.H., Grefhorst A., Abdelkarim M., Caron S., Torpier G., Fruchart J.-C., Gonzalez F.J. The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J.Biol. Chem. 2006, 281:11039-11049.
6. Carlson C.J., White M.F., Rondinone C.M. Mammalian target of rapamycin regulates IRS-1 serine 307 phosphorylation. Biochem. Biophys. Res. Commun. 2004, 316:533-539.
7. Chen H.C., Farese R.V. Determination of adipocyte size by computer image analysis. J.Lipid Res. 2002, 43:986-989.
8. Chen Z., Ma Run-mei Adipokines and insulin resistance. Med. Recapitul. 2011, 16:003.
9. Christiansen T., Richelsen B., Bruun J. Monocyte chemoattractant protein-1 is produced in isolated adipocytes, associated with adiposity and reduced after weight loss in morbid obese subjects. Int. J. Obes. 2005, 29:146-150.
10. Cipriani S., Mencarelli A., Palladino G., Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J.Lipid Res. 2010, 51:771-784.
11. Conde J., Scotece M., Gomez R., Lopez V., Gomez-Reino J.J., Lago F., Gualillo O. Adipokines: biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity. Biofactors 2011, 37:413-420.
12. Folch J., Lees M., Sloane-Stanley G. Asimple method for the isolation and purification of total lipids from animal tissues. J.Biol. Chem. 1957, 226:497-509.
13. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
14. Galic S., Oakhill J.S., Steinberg G.R. Adipose tissue as an endocrine organ. Mol. Cell. Endocrinol. 2010, 316:129-139.
15. Gao Z., Hwang D., Bataille F., Lefevre M., York D., Quon M.J., Ye J. Serine phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex. J.Biol. Chem. 2002, 277:48115-48121.
16. Gao Z., Zhang X., Zuberi A., Hwang D., Quon M.J., Lefevre M., Ye J. Inhibition of insulin sensitivity by free fatty acids requires activation of multiple serine kinases in 3T3-L1 adipocytes. Mol. Endocrinol. 2004, 18:2024-2034.
17. Ghebremariam Y.T., Yamada K., Lee J.C., Johnson C.L., Atzler D., Anderssohn M., Agrawal R., Higgins J.P., Patterson A.J., Böger R.H. FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats. PLoS One 2013, 8:e60653.
18. Gill H., Mugo M., Whaley-Connell A., Stump C., Sowers J.R. The key role of insulin resistance in the cardiometabolic syndrome. Am. J. Med. Sci. 2005, 330:290-294.
19. Hemati N., Ross S.E., Erickson R.L., Groblewski G.E., MacDougald O.A. Signaling pathways through which insulin regulates CCAAT/enhancer binding protein α (C/EBPα) phosphorylation and gene expression in 3T3-L1 adipocytes correlation with GLUT4 gene expression. J.Biol. Chem. 1997, 272:25913-25919.
20. Hollman D.A., Milona A., van Erpecum K.J., van Mil S.W. Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim. Biophys. Acta (BBA) Mol. Cell Biol. Lipids 2012, 1821:1443-1452.
21. Juge-Aubry C.E., Henrichot E., Meier C.A. Adipose tissue: a regulator of inflammation. Best Pract. Res. Clin. Endocrinol. Metab. 2005, 19:547-566.
22. Klöting N., Graham T.E., Berndt J., Kralisch S., Kovacs P., Wason C.J., Fasshauer M., Schön M.R., Stumvoll M., Blüher M. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007, 6:79-87.
23. Kohli R., Kirby M., Setchell K.D., Jha P., Klustaitis K., Woollett L.A., Pfluger P.T., Balistreri W.F., Tso P., Jandacek R.J. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity-related comorbidities. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299:G652-G660.
24. Kohli R., Bradley D., Setchell K.D., Eagon J.C., Abumrad N., Klein S. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J.Clin. Endocrinol. Metab. 2013, 98:E708-E712.
25. Kwon H., Pessin J.E. Adipokines mediate inflammation and insulin resistance. Front. Endocrinol. (Lausanne) 2013, 4:71.
26. Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 2009, 89:147-191.
27. Lew J.-L., Zhao A., Yu J., Huang L., de Pedro N., Peláez F., Wright S.D., Cui J. The farnesoid X receptor controls gene expression in a ligand-and promoter-selective fashion. J.Biol. Chem. 2004, 279:8856-8861.
28. Li Q., Chen R., Moriya J., Yamakawa J., Sumino H., Kanda T., Takahashi T. Anovel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. J.Int. Med. Res. 2008, 36:625-629.
29. McTernan C.L., McTernan P.G., Harte A.L., Levick P., Barnett A., Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet 2002, 359:46-47.
30. McTernan P.G., Fisher F.M., Valsamakis G., Chetty R., Harte A., McTernan C.L., Clark P.M., Smith S.A., Barnett A.H., Kumar S. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J.Clin. Endocrinol. Metab. 2003, 88:6098-6106.
31. Mruk D.D., Cheng C.Y. Enhanced chemiluminescence (ECL) for routine immunoblotting: an inexpensive alternative to commercially available kits. Spermatogenesis 2011, 1:121-122.
32. Nakatani H., Kasama K., Oshiro T., Watanabe M., Hirose H., Itoh H. Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. Metabolism 2009, 58:1400-1407.
33. Ouchi N., Parker J.L., Lugus J.J., Walsh K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 2011, 11:85-97.
34. Prawitt J., Caron S., Staels B. Bile acid metabolism and the pathogenesis of type 2 diabetes. Curr. Diabetes Rep. 2011, 11:160-166.
35. Rabe K., Lehrke M., Parhofer K.G., Broedl U.C. Adipokines and insulin resistance. Mol. Med. 2008, 14:741.
36. Reynoso R., Salgado L.M., Calderón V. High Levels of Palmitic Acid Lead to Insulin Resistance Due to Changes in the Level of Phosphorylation of the Insulin Receptor and Insulin Receptor Substrate-1, Vascular Biochemistry 2003, 155-162. Springer.
37. Rizzo G., Disante M., Mencarelli A., Renga B., Gioiello A., Pellicciari R., Fiorucci S. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function invivo. Mol. Pharmacol. 2006, 70:1164-1173.
38. Rodríguez-Sureda V., Peinado-Onsurbe J. Aprocedure for measuring triacylglyceride and cholesterol content using a small amount of tissue. Anal. Biochem. 2005, 343:277-282.
39. Rotter V., Nagaev I., Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-α, overexpressed in human fat cells from insulin-resistant subjects. J.Biol. Chem. 2003, 278:45777-45784.
40. Rubino F., R'bibo S.L., del Genio F., Mazumdar M., McGraw T.E. Metabolic surgery: the role of the gastrointestinal tract in diabetes mellitus. Nat. Rev. Endocrinol. 2010, 6:102-109.
41. Ryan K.K., Tremaroli V., Clemmensen C., Kovatcheva-Datchary P., Myronovych A., Karns R., Wilson-Pérez H.E., Sandoval D.A., Kohli R., Bäckhed F. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014, 509:183-188.
42. Senn J.J., Klover P.J., Nowak I.A., Mooney R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002, 51:3391-3399.
43. Skurk T., Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int. J. Obes. 2004, 28:1357-1364.
44. Skurk T., Alberti-Huber C., Herder C., Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J.Clin. Endocrinol. Metab. 2007, 92:1023-1033.
45. Srinivasan K., Viswanad B., Asrat L., Kaul C., Ramarao P. Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol. Res. 2005, 52:313-320.
46. Staels B., Fonseca V.A. Bile acids and metabolic regulation mechanisms and clinical responses to bile acid sequestration. Diabetes Care 2009, 32:S237-S245.
47. Sun X.J., Goldberg J.L., Qiao L., Mitchell J.J. Insulin-induced insulin receptor substrate-1 degradation is mediated by the proteasome degradation pathway. Diabetes 1999, 48:1359-1364.
48. Takahashi K., Mizuarai S., Araki H., Mashiko S., Ishihara A., Kanatani A., Itadani H., Kotani H. Adiposity elevates plasma MCP-1 levels leading to the increased CD11b-positive monocytes in mice. J.Biol. Chem. 2003, 278:46654-46660.
49. Thomas C., Pellicciari R., Pruzanski M., Auwerx J., Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 2008, 7:678-693.
50. Uchida K., Nomura Y., Takeuchi N. Effects of cholic acid, chenodeoxycholic acid, and their related bile acids on cholesterol, phospholipid, and bile acid levels in serum, liver, bile, and feces of rats. J.Biochem. 1980, 87:187-194.
51. Van Epps-Fung M., Williford J., Wells A., Hardy R.W. Fatty acid-induced insulin resistance in adipocytes 1. Endocrinology 1997, 138:4338-4345.
52. Wei J., Qiu D.K., Ma X. Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease. J.Dig. Dis. 2009, 10:85-90.
53. Yamamoto N., Ueda M., Sato T., Kawasaki K., Sawada K., Kawabata K., Ashida H. Measurement of Glucose Uptake in Cultured Cells, Current Protocols in Pharmacology 2001, John Wiley & Sons, Inc.
54. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., Kotani K., Quadro L., Kahn B.B. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
55. Yin D.P., Gao Q., Ma L.L., Yan W., Williams P.E., McGuinness O.P., Wasserman D.H., Abumrad N.N. Assessment of different bariatric surgeries in the treatment of obesity and insulin resistance in mice. Ann. Surg. 2011, 254:73.